Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Akebia Therapeutics, Inc.NASDAQ: AKBA
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income turns negative
Q1 FY2026 operating income was -$4.7M, compared with $13.51M a year earlier. Trailing-twelve-month operating income was $5.29M.
Context
- Operating income amounted to 9.9% of revenue in FY2025, down 21.6 pp from a year earlier.
- Operating income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 4 analysts of -$32.3M (-237.4%) for the fiscal year ending Dec 2026, a slowdown from the +146.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$4.7M+45.1% QoQ
- Last fiscal yearDec 2025
- $23.5M+146.6% YoY
- LTMMar 2026
- $5.29M+124.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -134.7% | -139.6% | -4.9 pp |
| 1 year | +146.6% | -237.4% | -384.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- 23.5M USD
- Year-over-year change
- +146.6%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.5M | +146.6% |
| FY2024 | 2024-12-31 | (50.47M) | -9.1% |
| FY2023 | 2023-12-31 | (46.26M) | +42.7% |
| FY2022 | 2022-12-31 | (80.78M) | +69.5% |
| FY2021 | 2021-12-31 | (264.5M) | — |
Operating Income vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's LTM Mar 2026 operating income of $5.29M is the 2nd highest of the 10 companies compared; the peer median is -$126.28M.
- Its year-over-year change of +124.0% is the 2nd highest of 9, against a peer median of -6.3%.
- Operating income amounts to 2.3% of revenue for AKBA, versus a peer median of 162.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.58M | +183.6% | — | 41.6% | |
| LTM Mar 2026 | $5.29M | +124.0% | — | 2.3% | |
| LTM Mar 2026 | -$47.93M | -53.5% | — | — | |
| LTM Mar 2026 | -$48.75M | +32.2% | — | 39.9% | |
| LTM Mar 2026 | -$75.17M | -21.6% | — | — | |
| LTM Mar 2026 | -$126.28M | +8.9% | — | 217.9% | |
| LTM Dec 2025 | -$140.01M | — | — | 120.8% | |
| LTM Mar 2026 | -$178.79M | -226.4% | — | 321.9% | |
| LTM Mar 2026 | -$179.55M | +11.7% | — | 203.5% | |
| LTM Mar 2026 | -$201.81M | -41.3% | — | — | |
| Peer median (excluding AKBA) | -$126.28M | -6.3% | — | 162.1% | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 211.65M | 292.48M | 194.62M | 160.18M | 236.2M |
| Cost of Revenue | 81.49M | 22.5M | 74.15M | 63.18M | 39.46M |
| Gross Profit | 130.16M | 269.99M | 120.47M | 97M | 196.73M |
| Gross Margin | 61.5% | 92.3% | 61.9% | 60.6% | 83.3% |
| Research & Development | 147.85M | 165.99M | 63.08M | 37.65M | 62.36M |
| Selling, General & Admin | 174.14M | 138.6M | 100.23M | 106.55M | 107.48M |
| Operating Expenses | 394.66M | 350.77M | 166.73M | 147.48M | 173.24M |
| Depreciation & Amortization | 37.97M | 37.7M | 37.63M | 37.5M | 1.27M |
| EBITDA | (189.91M) | 3.06M | (8.27M) | (13.72M) | 21.73M |
| EBITDA Margin | -89.7% | 1.0% | -4.2% | -8.6% | 9.2% |
| Operating Income | (264.5M) | (80.78M) | (46.26M) | (50.47M) | 23.5M |
| Operating Margin | -125.0% | -27.6% | -23.8% | -31.5% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 19.94M | 15.69M | 6.03M | 18.19M | 24.18M |
| Other Income / Expenses | (17.52M) | (13.45M) | (5.67M) | (18.94M) | (27.22M) |
| Income Before Tax | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (3.72M) |
| Pre-Tax Margin | -133.3% | -32.2% | -26.7% | -43.3% | -1.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.62M |
| Net Income | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (5.35M) |
| Net Margin | -133.3% | -32.2% | -26.7% | -43.3% | -2.3% |
| EPS (Basic) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| EPS (Diluted) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| Weighted Avg Shares | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
| Weighted Avg Shares (Diluted) | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.